Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Adrenal Gland Disorders01:27

Adrenal Gland Disorders

Adrenal gland disorders manifest when the production of adrenal hormones deviates from the norm, resulting in either excessive or insufficient concentrations.
Adrenal insufficiency, characterized by insufficient cortisol and aldosterone production, leads to conditions like Addison's disease. This disorder, affecting the adrenal cortex, exhibits symptoms such as skin bronzing, dehydration, low blood pressure, fatigue, and weight loss. Congenital adrenal hyperplasia, a genetic ailment causing...
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Liver Aging Index: A Noninvasive Score for Liver Biological Aging and Liver-Related Outcomes in Multicohorts.

Aging cell·2026
Same author

The Natural History and Individualized Prediction of Liver Stiffness-Based Fibrosis Risk in MASLD.

Clinical and molecular hepatology·2026
Same author

The use of pharmacotherapies in non-cirrhotic metabolic dysfunction-associated steatohepatitis: a UK expert consensus.

The lancet. Gastroenterology & hepatology·2026
Same author

FIB-4 fails to identify significant liver fibrosis in people with HIV: A large multinational screening study.

Hepatology (Baltimore, Md.)·2026
Same author

Prevalence of liver fibrosis in the general population (the LiverScreen project): a multinational European cohort study.

Lancet (London, England)·2026
Same author

Two-step clinical care pathway to predict MASLD-related advanced fibrosis and long-term outcomes in type 2 diabetes.

Gut·2026

Related Experiment Video

Updated: May 25, 2026

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
11:06

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

Adrenocortical dysfunction in liver disease: a systematic review.

Giuseppe Fede1, Luisa Spadaro, Tania Tomaselli

  • 1Internal Medicine, University of Catania-Garibaldi Hospital, Catania, Italy.

Hepatology (Baltimore, Md.)
|January 12, 2012
PubMed
Summary

Adrenal insufficiency (AI) is common in cirrhosis patients, impacting mortality. Current diagnostic tests and normal values for AI in liver disease lack standardization, necessitating further research.

More Related Videos

Human Liver Spheroids from Peripheral Blood for Liver Disease Studies
09:51

Human Liver Spheroids from Peripheral Blood for Liver Disease Studies

Published on: January 27, 2023

Related Experiment Videos

Last Updated: May 25, 2026

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
11:06

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

Human Liver Spheroids from Peripheral Blood for Liver Disease Studies
09:51

Human Liver Spheroids from Peripheral Blood for Liver Disease Studies

Published on: January 27, 2023

Area of Science:

  • Endocrinology
  • Hepatology
  • Critical Care Medicine

Background:

  • Adrenal insufficiency (AI) is frequently observed in cirrhosis patients, particularly during sepsis and septic shock, correlating with increased mortality.
  • The term "hepato-adrenal syndrome" has been proposed due to the high incidence of AI in various stages of liver disease, including stable cirrhosis, decompensation (bleeding, ascites), and post-liver transplantation.
  • Corticosteroid therapy efficacy in critically ill liver disease patients remains controversial, highlighting the need for better diagnostic tools.

Purpose of the Study:

  • To review and evaluate existing data on adrenal function in patients with liver disease.
  • To identify limitations in current studies and propose directions for future research.
  • To address the lack of consensus on diagnostic methods and normal values for AI in liver disease.

Main Methods:

  • Review of published literature on adrenal function in liver disease.
  • Analysis of diagnostic challenges, including the utility of the 250-μg adrenocorticotropic hormone stimulation test.
  • Discussion of alternative diagnostic approaches like direct free cortisol measurement.

Main Results:

  • Serum total cortisol assays may overestimate AI in cirrhosis.
  • Standardization of normal ranges and methodologies for adrenal function testing in liver disease is lacking.
  • Mechanisms underlying liver disease-induced adrenal dysfunction require further investigation.

Conclusions:

  • There is a critical need for standardized diagnostic tests and normal values for adrenal function assessment in liver disease.
  • Direct free cortisol measurement or its surrogates may offer more accurate AI assessment in cirrhosis.
  • Further research is essential to elucidate the mechanisms of adrenal dysfunction in liver disease and optimize patient management.